Cargando…

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study

To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005–2012 period were identified in the Danish National Multiple Myeloma Registry. For...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gregersen, Henrik, Vangsted, Annette Juul, Abildgaard, Niels, Andersen, Niels Frost, Pedersen, Robert Schou, Frølund, Ulf Christian, Helleberg, Carsten, Broch, Bettina, Pedersen, Per Trøllund, Gimsing, Peter, Klausen, Tobias Wirenfeldt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504337/ https://www.ncbi.nlm.nih.gov/pubmed/28639741 http://dx.doi.org/10.1002/cam4.1128

Ejemplares similares

The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
por: Gregersen, Henrik, et al.
Publicado: (2018)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
por: Vangsted, Annette J, et al.
Publicado: (2010)

Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation
por: Bertelsen, Lise Dueholm, et al.
Publicado: (2022)

Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study
por: Larsen, Rikke Faebo, et al.
Publicado: (2020)

Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial
por: Johnsen, Hans E, et al.
Publicado: (2009)

The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey
por: Redder, Louise, et al.
Publicado: (2021)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma—a randomized controlled feasibility study
por: Larsen, Rikke Faebo, et al.
Publicado: (2019)

Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
por: Schmitz, Alexander, et al.
Publicado: (2022)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Strategies to improve patient-reported outcome completion rates in longitudinal studies
por: Nielsen, Lene Kongsgaard, et al.
Publicado: (2019)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Cardiovascular events in cancer patients with bone metastases—A Danish population‐based cohort study of 23,113 patients
por: Asdahl, Peter H., et al.
Publicado: (2021)

Germline variants at SOHLH2 influence multiple myeloma risk
por: Duran-Lozano, Laura, et al.
Publicado: (2021)

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
por: Gundesen, Michael, et al.
Publicado: (2023)

Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
por: Duran-Lozano, Laura, et al.
Publicado: (2021)

Implementation of p16/Ki67 dual stain cytology in a Danish routine screening laboratory: Importance of adequate training and experience
por: Hammer, Anne, et al.
Publicado: (2020)

HIV Care in the Swedish-Danish HIV Cohort 1995-2010, Closing the Gaps
por: Helleberg, Marie, et al.
Publicado: (2013)

Development over time in point-of-care test use in Danish daytime and out-of-hours general practice: a register-based study
por: Kjær, Niels, et al.
Publicado: (2023)

The Danish Cerebral Palsy Follow-up Program
por: Rasmussen, Helle Mätzke, et al.
Publicado: (2016)

The Danish National Acute Leukemia Registry
por: Østgård, Lene Sofie Granfeldt, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system
por: Jonasson, Elise, et al.
Publicado: (2023)

Ethnic differences in leptin and adiponectin levels between Greenlandic Inuit and Danish children
por: Munch-Andersen, Thor, et al.
Publicado: (2013)

Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients
por: Øvlisen, Andreas K., et al.
Publicado: (2020)

Multiple Myeloma Associated Bone Disease
por: Rasch, Stine, et al.
Publicado: (2020)

Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation
por: Andersen, Morten Nørgaard, et al.
Publicado: (2017)

Lung cancer in HIV patients and their parents: A Danish cohort study
por: Engsig, Frederik N, et al.
Publicado: (2011)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Risk of Hidradenitis Suppurativa Comorbidities Over Time: A Prospective Cohort Study of Danish Blood Donors
por: ANDERSEN, Rune Kjærsgaard, et al.
Publicado: (2021)

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro
por: Lund, Thomas, et al.
Publicado: (2010)

BENEFIT for all: An ecosystem to facilitate sustained healthy living and reduce the burden of cardiovascular disease
por: Keesman, Mike, et al.
Publicado: (2018)

Head and neck cancer in HIV patients and their parents: a Danish cohort study
por: Engsig, Frederik N, et al.
Publicado: (2011)

The prevalence of comorbidities in Danish patients with obesity – A Danish register‐based study based on data from 2002 to 2018
por: Pedersen, Mikkel H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b5al54rl41apr7mf1q0tddj85g